NICE approves new drug for chronic kidney disease and diabetes
Results from a phase III study of more than 5,000 adults suggested that finerenone improved kidney function and helped slow the worsening of chronic kidney disease.
Finerenone, marketed as Kerendia by Bayer, is recommended only as an add-on to optimised standard care and if the person has an estimated glomerular filtration rate of 25mL/min/1.73 m2 or more
JHVEPhoto / Alamy Stock Photo
The National Institute for Health and Care Excellence (NICE) has recommended a new medicine for adults with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM).
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
